Skip to main content
When exposed to radiation, electrons produced within molten zinc chloride, or ZnCl2, can be observed in three distinct singly occupied molecular orbital states, plus a more diffuse, delocalized state. Credit: Hung H. Nguyen/University of Iowa

In a finding that helps elucidate how molten salts in advanced nuclear reactors might behave, scientists have shown how electrons interacting with the ions of the molten salt can form three states with different properties. Understanding these states can help predict the impact of radiation on the performance of salt-fueled reactors.

ORNL’s David Sholl is director of the new DOE Energy Earthshot Non-Equilibrium Energy Transfer for Efficient Reactions center to help decarbonize the industrial chemical industry. Credit: Genevieve Martin, ORNL/U.S. Dept. of Energy

ORNL has been selected to lead an Energy Earthshot Research Center, or EERC, focused on developing chemical processes that use sustainable methods instead of burning fossil fuels to radically reduce industrial greenhouse gas emissions to stem climate change and limit the crisis of a rapidly warming planet.
 

TIP graphic

Scientist-inventors from ORNL will present seven new technologies during the Technology Innovation Showcase on Friday, July 14, from 8 a.m.–4 p.m. at the Joint Institute for Computational Sciences on ORNL’s campus.

Oak Ridge National Laboratory has signed a memorandum of understanding with the United Kingdom’s National Nuclear Laboratory to partner on various nuclear research and development efforts.

The United Kingdom’s National Nuclear Laboratory and the U.S. Department of Energy’s Oak Ridge National Laboratory have agreed to cooperate on a wide range of nuclear energy research and development efforts that leverage both organizations’ unique expertise and capabilities.

Radiochemical technicians David Denton and Karen Murphy use hot cell manipulators at Oak Ridge National Laboratory during the production of actinium-227.

The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.